Jean-Luc GALA

Prof. Dr. Jean-Luc GALA

Center for Applied Molecular Technologies, Université Catholique de Louvain, Louvain-la-Neuve, Wallonia, Belgium
orcid
Mobile laboratory B-LiFE, GOARN, applied molecular technolo...

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2017 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
TNThi Huyen Tram Nguyen
Thi Huyen Tram Nguyen
JGJeremie Guedj
Jeremie Guedj
XAXavier Anglaret
Xavier Anglaret
CLCédric LAOUENAN
Cédric LAOUENAN
VMVincent Madelain
Vincent Madelain
FMFrance Mentré
France Mentré
In 2014–2015, we assessed favipiravir tolerance and efficacy in patients with Ebola virus (EBOV) disease (EVD) in Guinea (JIKI trial). Because the drug had never been used before for this indication and that high concentrations of the drugs were needed to achieve antiviral efficacy against EBOV, a pharmacokinetic model had been used to propose relevant dosing regimen. Here we report the favipiravir plasma concentrations that were achieved in participants in the JIKI trial and put them in perspective with the model-based targeted concentrations. Pre-dose drug concentrations were collected at Day-2 and Day-4 of treatment in 66 patients of the JIKI trial and compared to those predicted by the model taking into account patient’s individual characteristics. At Day-2, the observed concentrations were slightly lower than the model predictions adjusted for patient’s characteristics (median value of 46.1 versus 54.3 μg/mL for observed and predicted concentrations, respectively, p = 0.012). However, the concentrations dropped at Day-4, which was not anticipated by the model (median values of 25.9 and 64.4 μg/mL for observed and predicted concentrations, respectively, p<10−6). There was no significant relationship between favipiravir concentrations and EBOV viral kinetics or mortality. Favipiravir plasma concentrations in the JIKI trial failed to achieve the target exposure defined before the trial. Furthermore, the drug concentration experienced an unanticipated drop between Day-2 and Day-4. The origin of this drop could be due to severe sepsis conditions and/or to intrinsic properties of favipiravir metabolism. Dose-ranging studies should be performed in healthy volunteers to assess the concentrations and the tolerance that could be achieved with high doses. ClinicalTrials.gov NCT02329054 In 2014–2015, the JIKI trial was conducted in Guinea to test favipiravir tolerance and efficacy in patients with Ebola virus disease (EDV). The main results of the trial were previously published without drug concentrations which were not available at the time of publication. The purpose of this study was to report favipiravir concentrations achieved in participants in the JIKI trial and to compare them with the targeted concentrations. We analyzed drug concentrations obtained at Day-2 and Day-4 and compared them to the targeted concentrations. At Day-2, favipiravir concentrations were significantly below but still close to the targeted concentration. At Day-4, a significant and unanticipated drop of concentrations as compared to Day-2 was observed. The origin of the lower-than-targeted concentrations and the unexpected drop could be due to severe sepsis conditions and/or to intrinsic properties of favipiravir metabolism. No significant correlation was found between the drug exposure and the virological response, indicating that it is possible that the favipiravir concentrations in the JIKI trial were not sufficient to strongly inhibit the viral replication. These findings suggest the necessity of performing dose-ranging studies with high doses of favipiravir in healthy volunteers to inform any further development of favipiravir for treatment of EVD.

20 January 2012 in Applied Microbiology and Biotechnology
Verified
Journal Article
Closed access
PDF file
LILéonid M. Irenge
Léonid M. Irenge
Jean-Luc GALAJean-Luc GALA
Jean-Luc GALA

1 November 2008 in The Journal of Molecular Diagnostics
Verified
Journal Article
Closed access
BVBernard Vandercam
Bernard Vandercam
SJSabine Jeumont
Sabine Jeumont
OCOlivier Cornu
Olivier Cornu
JYJean-Cyr Yombi
Jean-Cyr Yombi
FLFrédéric Lecouvet
Frédéric Lecouvet
Jean-Luc GALAJean-Luc GALA
Jean-Luc GALA

7 December 2012 in Parasites & Vectors
Verified
Journal Article
Open access
PDF file
JDJean-Francois Durant
Jean-Francois Durant
LILeonid M Irenge
Leonid M Irenge
RFRenata Fogt-Wyrwas
Renata Fogt-Wyrwas
CDCatherine Dumont
Catherine Dumont
JDJean-Pierre Doucet
Jean-Pierre Doucet
Jean-Luc GALAJean-Luc GALA
Jean-Luc GALA
Background: Toxocarosis is a zoonotic disease caused by Toxocara canis (T. canis) and/or Toxocara cati (T. cati), two worldwide distributed roundworms which are parasites of canids and felids, respectively. Infections of humans occur through ingestion of embryonated eggs of T. canis or T. cati, when playing with soils contaminated with dogs or cats feces. Accordingly, the assessment of potential contamination of these areas with these roundworms eggs is paramount. Methods: A duplex quantitative real-time PCR (2qPCR) targeting the ribosomal RNA gene internal transcribed spacer (ITS2) has been developed and used for rapid and specific identification of T. canis and T. cati eggs in fecal and soil samples. The assay was set up on DNA samples extracted from 53 adult worms including T. canis, T. cati, T. leonina, Ascaris suum (A. suum) and Parascaris equorum (P. equorum). The assay was used to assess the presence of T. cati eggs in several samples, including 12 clean soil samples spiked with eggs of either T. cati or A. suum, 10 actual soil samples randomly collected from playgrounds in Brussels, and fecal samples from cats, dogs, and other animals. 2qPCR results on dogs and cats fecal samples were compared with results from microscopic examination. Results: 2qPCR assay allowed specific detection of T. canis and T. cati, whether adult worms, eggs spiked in soil or fecal samples. The 2qPCR limit of detection (LOD) in spiked soil samples was 2 eggs per g of soil for a turnaround time of 3 hours. A perfect concordance was observed between 2qPCR assay and microscopic examination on dogs and cats feces. Conclusion: The newly developed 2qPCR assay can be useful for high throughput prospective or retrospective detection of T.canis and/or T. cati eggs in fecal samples as well as in soil samples from playgrounds, parks and sandpits.

11 February 2019 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
LILeonid M. Irenge
Leonid M. Irenge
JAJérôme Ambroise
Jérôme Ambroise
BBBertrand Bearzatto
Bertrand Bearzatto
JDJean-Francois Durant
Jean-Francois Durant
RCRaphaël B. Chirimwami
Raphaël B. Chirimwami
Jean-Luc GALAJean-Luc GALA
Jean-Luc GALA
Extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli are responsible for severe infections worldwide. Whereas their genotypic and pathogenic characteristics are not documented in Democratic Republic of Congo (DRC), recent studies conducted at the Bukavu General Hospital in the South Kivu province highlighted their high prevalence in extra-intestinal infections. Here we provide data on molecular characterization of ESBL producing-Escherichia coli isolates from patients with extra-intestinal infections at this provincial hospital. Whole-genome sequencing was carried out on 21 of these ESBL-producing Extra-intestinal Pathogenic Escherichia coli (ExPEC) for analysis of phylogenomic evolution, virulence factor and antimicrobial resistance (AMR) genes. Data were compared to phylogenetically close genomes using Multi-Locus Sequence Typing and Single Nucleotide Polymorphism-based phylogenetic approaches. The distribution of E. coli sequence types (ST) was as follows: ST 131 (n = 7), ST405 (n = 4), ST410 (n = 2), and other STs (ST10, ST58, ST95, ST393, ST443, S617, ST648, and ST2450). All ST131 belonged to the O25b-ST131 pandemic clone. Unexpectedly, they harbored more virulence genes than their GenBank counterparts. IncF plasmid replicons included novel FIB 69, FII 105 and FII 107 alleles. ESBL-genes included the plasmid-mediated CTX-M-15 in all isolates, and the SHV-12 allele. Other AMR genes included blaOXA-1, blaTEM-1, as well as genes encoding resistance against aminoglycosides, quinolones, chloramphenicol, rifampicin, tetracyclines, sulfonamides and trimethoprim. Current data confirm the clonal spread of ESBL-producing ST131 and ST405 clones in patients from South Kivu, and the acquisition of resistance and virulence genes. A closer survey of AMR and virulence should therefore be prompted in this high-risk area.

18 June 2014 in BMC Research Notes
Verified
Journal Article
Open access
PDF file
LILeonid M Irenge
Leonid M Irenge
LKLandry Kabego
Landry Kabego
OVOlivier Vandenberg
Olivier Vandenberg
RCRaphael B Chirimwami
Raphael B Chirimwami
Jean-Luc GALAJean-Luc GALA
Jean-Luc GALA
The rate of antimicrobial resistant isolates among pathogens causing urinary tract infections (UTIs) in Democratic Republic of Congo (DRC) is not known. The aim of the current study was to determine this rate at the Bukavu Provincial General Hospital (province of South-Kivu, DRC).